ReviewFrontiers in immunology2024
Chemokines in the tumor microenvironment: implications for lung cancer and immunotherapy.
Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping research trends in macrophage polarization and immunotherapeutic potential in prostate cancer: a bibliometric and visual analysis.Frontiers in oncology · 2026Pooled it
- Innate Immune Cells in Non-Small Cell Lung Cancer: Roles in Tumor Progression and Therapeutic Responses.Cancer innovation · 2026Review
- Technical review of artificial intelligence in TCR-T therapy.Journal of the National Cancer Center · 2026Review
- VEGFC as a prognostic cytokine biomarker linking lymph node metastasis to immune suppression in breast cancer.European cytokine network · 2026Article
- Radiotherapy combined with immunotherapy for esophageal cancer: current status and challenge.Journal of cancer research and clinical oncology · 2026Review
- Oncogenic role and potential mechanisms of MYO1B in breast cancer.In vitro cellular & developmental biology. Animal · 2026Article
- Suppressive effects on metastasis and tumor growth by the knockout of chemokine receptors in a canine cutaneous lymphoma model.The Journal of veterinary medical science · 2026Article
- Systematic evaluation of a novel mesoporous silica nanoparticles (MSNs)-RSC advances · 2026Article
- Rearming mesenchymal stem cells with engineering strategies to combat cancer.Frontiers in immunology · 2026Review
- Integrating chemokine signatures and multi-omic biomarkers to predict immunotherapy response in non-small cell lung cancer: a comprehensive narrative review.Frontiers in oncology · 2026Review
- Tumor-embedded Immunity and TRM Cell Functions in Cancer.Mini reviews in medicinal chemistry · 2026Review
- Regulating the regulators via targeting CD38 in the tumor microenvironment.Frontiers in immunology · 2026Review
- Eosinophils in lung cancer: from inflammatory cytokines to immunotherapeutic biomarkers.Frontiers in immunology · 2026Review
- Orbital Metastases of Breast Cancer: Case Report and Review of the Literature.Oncology research · 2026Review
- CCR5 expression and conformational stability as potential cooperative modulators of immune phenotypes and therapy response in breast cancer.Discover oncology · 2025Article
- Correspondence on "METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5/CCL5 regulation" by TongJournal for immunotherapy of cancer · 2025Article
- Article
- HIFU-CCL19/21 Axis Enhances Dendritic Cell Vaccine Efficacy in the Tumor Microenvironment.Pharmaceutics · 2025Article
- Tumor-Associated Macrophages in Lung Cancer: Origins, Functional Heterogeneity, and Therapeutic Implications.Journal of inflammation research · 2025Review
- Tumor-infiltrating lymphocytes and tumor-associated macrophages in cancer immunoediting: a targetable therapeutic axis.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The tumor microenvironment (TME) is a complex interconnected network of immune cells, fibroblasts, blood vessels, and extracellular matrix surrounding the tumor. Because of its immunosuppressive nature, the TME can pose a challenge for cancer immunotherapies targeting solid tumors. Chemokines have emerged as a crucial element in enhancing the efficacy of cancer immunotherapy, playing a direct role in immune cell signaling within the TME and facilitating immune cell migration towards cancer cells. However, chemokine ligands and their receptors exhibit context-dependent diversity, necessitating evaluation of their tumor-promoting or inhibitory effects based on tumor type and immune cell characteristics. This review explores the role of chemokines in tumor immunity and metastasis in the context of the TME. We also discuss current chemokine-related advances in cancer immunotherapy research, with a particular focus on lung cancer, a common cancer with a low survival rate and limited immunotherapy options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.